On Friday, AtriCure received a positive adjustment to its Relative Strength (RS) Rating, from 69 to 74.
How To Invest In Stocks In Both Bull And Bear Markets
This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 as they begin their largest runs. See if AtriCure can continue to show renewed price strength and hit that benchmark.
AtriCure is building a cup with handle with a 38.33 entry. See if the stock can break out in heavy trade.
AtriCure posted 0% earnings growth in the latest quarterly report. Revenue rose 17%.
AtriCure holds the No. 8 rank among its peers in the Medical-Systems/Equipment industry group. iRadimed, IDEXX Laboratories and Brainsway ADR are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Price Performance?
